Erratum to “Effects of diabetes mellitus in patients with heart failure and chronic kidney disease: A propensity-matched study of multimorbidity in chronic heart failure” [Int. J. Cardiol. 134 (2009) 330–335]

2010 ◽  
Vol 138 (1) ◽  
pp. 106
Author(s):  
Christine Ritchie ◽  
O. James Ekundayo ◽  
Maureen Muchimba ◽  
Ruth C. Campbell ◽  
Stuart J. Frank ◽  
...  
2009 ◽  
Vol 103 (1) ◽  
pp. 88-92 ◽  
Author(s):  
O. James Ekundayo ◽  
Maureen Muchimba ◽  
Inmaculada B. Aban ◽  
Christine Ritchie ◽  
Ruth C. Campbell ◽  
...  

Author(s):  
Н. И. Гуляев ◽  
И. М. Ахметшин ◽  
А. В. Гордиенко ◽  
В. В. Яковлев

Цель работы - сопоставление показателей СКФ, рассчитанных на основании сывороточных концентраций креатинина и цистатина С у 86 пациентов 60-92 лет (средний возраст - 75±7 лет) с ХСН и саркопенией. СКФ рассчитывали по формулам на основе креатинина ( CKD-EPIСr ), цистатина С ( CKDEPIСys ) крови и обоих маркеров ( CKD-EPIСr-Cys ). Концентрацию цистатина С в сыворотке крови определяли иммунотурбидиметрическим методом, креатинина - Яффе-кинетическим методом. У всех больных исследован композитный состав тела с помощью двуэнергетической рентгеновской абсорбциометрии с расчетом индекса саркопении (по критериям FNIH, 2014 г.) и измерена общая жировая масса. Проведены тест с 6-минутной ходьбой, оценка по шкале ШОКС, трансторакальная эхо-КГ с измерением конечного диастолического размера, конечного систолического размера, ФВ ЛЖ, массы миокардаЛЖ, индекса массы миокарда ЛЖ, показателей диастолической функции ЛЖ. В зависимости от критериев диагностики саркопении пациенты были разделены на две группы: 1-я ( n =42) - сочетание ХСН и саркопении; 2-я ( n =44) - ХСН без саркопении. У больных с ХСН и саркопенией наблюдали переоценку СКФ, рассчитанной по уровню креатинина, на 23% (абсолютная разница - более 18 мл/мин на 1,73 м) по сравнению с СКФ, оцененной по уровню цистатина С . У больных с ХСН и саркопенией при использовании сывороточной концентрации креатинина имеет место гиподиагностика выраженности хронической болезни почек. В этой связи при наличии признаков саркопении для расчета СКФ рекомендуется использовать формулу CKD-EPIСys . The purpose of the research is comparison of glomerular filtration rate calculated on the basis of serum concentrations of creatinine and cystatin C in patients with chronic heart failure and sarcopenia. In this research 86 patients with chronic heart failure and sarcopenia aged 60 to 92 years (mean age 75±7 years) were examined. GFR calculation was determined using formulas based on creatinine ( CKD-EPIC ), cystatin C ( CKD-EPICys ) in blood and both markers ( CKD-EPICr-Cys ). The concentration of cystatin C in blood serum was determined by the immunoturbidimetric method, and creatinine by the Jaffe kinetic method. Composite body composition was studied in all patients using dual-energy X -ray absorptiometry with calculation of the sarcopenia index (according to FNIH criteria, 2014) and measurement of total fat mass. A test with a 6-minute walk, an assessment according to the SHOKS scale (clinical condition assessment scale for CHF), transthoracic echocardiography with the measurement of EDD, ESD, LVEF, LVМ, LVIM, indicators of LV diastolic function was performed. Depending on the diagnostic criteria for sarcopenia, patients were divided into 2 groups: the first - a combination of heart failure and sarcopenia; the second - CHF without sarcopenia. In patients with CHF and sarcopenia, GFR was reassessed as calculated by the creatinine level by 23 % (the absolute difference is more than 18 ml/min/1,73 m) compared with GFR estimated by the level of cystatin C . In patients with heart failure and sarcopenia, when using a serum concentration of creatinine, there is a hypodiagnostics of the severity of chronic kidney disease. In this regard, if there are signs of sarcopenia, it is recommended to use the formula CKD-EPICys to calculate GFR.


Circulation ◽  
2020 ◽  
Vol 142 (Suppl_3) ◽  
Author(s):  
Koichiro Watanabe ◽  
Yu Sato ◽  
Akiomi YOSHIHISA ◽  
Yasuhiro Ichijo ◽  
Yu Hotsuki ◽  
...  

Backgrounds: The associations between red blood cell distribution width and prognosis in patients with heart failure (HF) have been reported. However, the prognostic impact of platelet distribution width (PDW) has been unclear in HF patients. Methods: We conducted a prospective observational study. We analyzed data on 1,746 hospitalized patients with HF who discharged alive and measured PDW at stable condition in prior to discharge. Patients were divided into tertiles based on levels of PDW: 1 st (PDW < 15.9 fL, n = 586), 2 nd (PDW 15.9-16.8 fL, n = 617), and 3 rd (PDW ≥ 16.9, n = 543) tertiles. We compared baseline patients’ characteristics and their post-discharge prognosis such as all-cause death, cardiac death, and cardiac events including cardiac death and re-hospitalization due to worsening HF. Results: Prevalence of diabetes mellitus, anemia, and chronic kidney disease was highest in the 3 rd tertile than in the 1 st and 2 nd tertiles (diabetes mellitus, 42.7% vs. 40.3% and 30.5%, P < 0.001; anemia, 52.5% vs. 48.3% and 41.2%, P < 0.001; chronic kidney disease, 57.5% vs. 49.0% and 49.3%, P = 0.005). Age was oldest and B-type natriuretic peptide levels were highest in the 3 rd tertile compared to the 1 st and 2 nd tertiles (age, 70.0, vs. 69.0 and 68.0 years old, P = 0.038; B-type natriuretic peptide, 241.0 vs. 235.2 and 171.9 pg/mL, P < 0.001). In contrast, sex and left ventricular ejection fraction did not differ among the groups. The Kaplan-Meier analysis ( Figure ) demonstrated that rates of all endpoints were the highest in the 3 rd tertile among the groups (log-rank P < 0.001, respectively). The Cox proportional hazard analysis adjusted for potential confounding factors revealed that the 3 rd tertile was independently associated with adverse prognosis (all-cause death, hazard ratio [HR] 1.312, P = 0.042; cardiac death, HR 1.422, P = 0.046; cardiac event, HR 1.283, P = 0.041). Conclusion: PDW is a novel independent predictor of adverse prognosis in patients with HF.


2008 ◽  
Vol 24 (1) ◽  
pp. 186-193 ◽  
Author(s):  
R. C. Campbell ◽  
X. Sui ◽  
G. Filippatos ◽  
T. E. Love ◽  
C. Wahle ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document